Noboru Hattori
Overview
Explore the profile of Noboru Hattori including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
270
Citations
2740
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kitadai E, Yamaguchi K, Iwamoto H, Shimoji K, Sakamoto S, Horimasu Y, et al.
Lung
. 2025 Mar;
203(1):43.
PMID: 40074958
Purpose: Toll-like receptor 4 (TLR4) is a transmembrane receptor promoting pro-inflammatory signalling, that is associated with the pathogenesis of pulmonary fibrosis. TLR4 is abundantly expressed on monocytes and the acceleration...
2.
Hirakawa T, Yamaguchi K, Funaishi K, Shimoji K, Sakamoto S, Horimasu Y, et al.
Cancers (Basel)
. 2025 Feb;
17(4).
PMID: 40002167
Background/objectives: Vascular endothelial growth factor (VEGF)-A promotes an immunosuppressive tumor microenvironment, potentially affecting the efficacy of anti-programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) antibody therapy. VEGF and...
3.
Funaishi K, Yamaguchi K, Tanahashi H, Kurose K, Sakamoto S, Horimasu Y, et al.
Cancer Chemother Pharmacol
. 2025 Jan;
95(1):28.
PMID: 39853458
Background: The expression of anti-programmed cell death ligand-1 (PD-L1) in tumors is widely used as a biomarker to predict the therapeutic efficacy of anti-programmed cell death-1(PD-1)/PD-L1 antibodies. However, the predictive...
4.
Inada S, Omori K, Nomura T, Kitagawa H, Shigemoto N, Hattori N, et al.
J Infect Chemother
. 2024 Dec;
31(3):102596.
PMID: 39710166
Immune checkpoint inhibitors (ICIs) have been approved for treating various cancers; however, they can cause immune-related adverse events. Generally, ICIs are not associated with an increased risk of infection, however,...
5.
Nomura N, Matsumoto H, Asano K, Hayashi Y, Yokoyama A, Nishimura Y, et al.
J Allergy Clin Immunol Glob
. 2024 Dec;
4(1):100364.
PMID: 39659740
Background: Sensitization to mucus plugs, and bacterial colonization may coexist and relate to a refractory phenotype during follow-up in asthma with bronchiectasis and allergic bronchopulmonary aspergillosis (ABPA). Objective: This study...
6.
Sugiyama A, Kataoka M, Tokumo K, Abe K, Imada H, Sun B, et al.
J Epidemiol
. 2024 Dec;
PMID: 39647911
BackgroundWith global aging, especially in Asia, preventing pneumonia among seniors is vital. The necessity of introducing pneumococcal vaccines among the elderly has been highlighted but there is a paucity of...
7.
Kitadai E, Yamaguchi K, Ohshimo S, Iwamoto H, Sakamoto S, Horimasu Y, et al.
Respir Res
. 2024 Nov;
25(1):405.
PMID: 39529063
Background: The receptor for advanced glycation end product (RAGE) is a transmembrane receptor accelerating a pro-inflammatory signal. RAGE signalling is promoted by decreased soluble isoform of RAGE (sRAGE), which is...
8.
Koyauchi T, Fujisawa T, Miyashita M, Mori M, Morita T, Yazawa S, et al.
Ann Am Thorac Soc
. 2024 Nov;
22(3):395-402.
PMID: 39513985
Accurate prognostic awareness (PA) and knowledge of the disease are critical for decision-making regarding treatment options, advance care planning, and end-of-life care. However, they have not been investigated in patients...
9.
Egusa H, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Kushitani K, et al.
Case Rep Oncol
. 2024 Oct;
17(1):1115-1123.
PMID: 39474544
Introduction: There have been only a few cases showing the efficacy of pembrolizumab on granulocyte-colonystimulating factor (G-CSF)-producing non-small-cell lung cancer (NSCLC) with high programmed cell death ligand 1 (PD-L1) expression....
10.
Masuda T, Tsubata Y, Hata K, Horie M, Kiura K, Kanaji N, et al.
Thorac Cancer
. 2024 Oct;
15(34):2408-2417.
PMID: 39415454
Introduction: Studies have shown the antitumor efficacy of immune checkpoint inhibitors (ICI) in patients with non-small cell lung cancer (NSCLC) and brain metastases (BM). However, it is unclear whether the...